Imaging Core

成像核心

• 批准号: 10620831
• 负责人: Richard E. Carson
• 金额: $ 34.71万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620831
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer’s disease biomarker; Amyloid; Atlases; Autopsy; Behavior; Behavioral Model; Binding; Biological Markers; Brain; Clinical; Clinical Research; Clinical Trials; Cognitive; Data; Data Analyses; Data Set; Development; Dimensions; Disease Pathway; Disease Progression; Functional Magnetic Resonance Imaging; Functional disorder; Future; Goals; Hippocampus; Human; Image; Image Analysis; Imaging Device; Imaging technology; Individual; Infrastructure; Link; Magnetic Resonance; Magnetic Resonance Imaging; Measurable; Measures; Methodology; Methods; Modeling; Multimodal Imaging; NIH Program Announcements; Nerve Degeneration; Noise; Paper; Participant; Patients; Pattern; Phenotype; Positron-Emission Tomography; Principal Investigator; Radiation Dose Unit; Research; Research Personnel; Resolution; Resources; Scanning; Statistical Data Interpretation; Statistical Models; Structure; Study Subject; Synapses; System; Techniques; Tracer; Training; Work; aged; analytical method; connectome; connectome based predictive modeling; data management; deep learning; density; experience; fluorodeoxyglucose; glucose metabolism; human data; human imaging; human subject; imaging biomarker; imaging study; in vivo; in vivo imaging; innovation; mild cognitive impairment; multimodal data; multimodality; neuroimaging; neuropathology; next generation; nonhuman primate; novel; novel strategies; pre-clinical; programs; research study; success; tau Proteins

Project Summary: Yale ADRC Imaging Core The Yale Alzheimer Disease Research Center has the overall goal to advance understanding and treatment of Alzheimer’s disease (AD). This effort requires integration of a wide array of core functions, including Clinical, Neuropathology, and Neuroimaging. Human imaging studies allow for the development of imaging biomarkers of AD, characterization of the temporal sequence of AD pathology, and lead to better assignment of patients to clinical research studies and clinical trials. Imaging is a major strength at Yale, as exemplified by the breadth and depth offered by the Yale PET Center and the Yale Magnetic Resonance Research Center (MRRC). In the PET Center, an example of recent significant work is the introduction of PET synaptic imaging with the SV2A tracer 11C-UCB-J. In MRI, the Yale MRRC has generated numerous novel methods to characterize an individual’s functional connectome and relate the functional organization to behavior and clinical variables Overall, these two Centers develop cutting edge imaging technologies and apply these techniques to answer important clinical questions. By creating this Yale ADRC Imaging Core (YAIC), we leverage the vast experience of Yale’s imaging strengths to provide state-of-the-art acquisition and analysis of imaging data and to focus on the development of novel approaches to AD. The YAIC will provide a common infrastructure for acquisition, processing, and analysis of multimodal imaging data, to support and train AD investigators and develop the next generation of imaging tools. The current and future methods will be applied to ongoing imaging studies to acquire a rich, multi-faceted and multi-modality dataset in human subjects. In addition, the translational component of this program examines the utility of nonhuman primates (NHPs) as a model for human AD. The Imaging Core will perform the following specific aims: Aim 1: To develop and optimize PET image and data analysis strategies to facilitate within- and between-subject comparisons. Multi-tracer within- subject correlations are important, involving amyloid, tau, synaptic density, and glucose metabolism. Aim 2: To enhance our MR-based functional connectome modeling to better functionally phenotype patients and link brain to behavior. This approach provides a functional profile for each individual while localizing the networks and revealing the network organizing principles supporting these functions. Aim 3: To develop and enrich multi- modality analyses between PET and fMRI for within- and between-subject studies. The combination of fMRI- based connectivity with the regional patterns of neurodegeneration measurable with PET provides an ideal opportunity for understanding the pathways of disease progression. Aim 4: To extend the methodologies developed for human analysis to NHP data. Ongoing studies in aged NHPs are being performed, providing the opportunity to compare in vivo PET and MR imaging with post-mortem measures provided by the Neuropathology Core.

项目摘要：耶鲁ADRC成像核心 耶鲁阿尔茨海默氏病研究中心的总体目标是提高对 阿尔茨海默氏病（AD）。这项工作需要集成各种核心功能，包括临床， 神经病理学和神经影像学。人类成像研究允许发展成像生物标志物 AD的表征AD病理的临时序列，并使患者更好地分配患者 临床研究和临床试验。成像是耶鲁大学的主要优势，例如 耶鲁宠物中心和耶鲁磁共振研究中心（MRRC）提供的深度。在 宠物中心，最近重大工作的一个例子是用SV2A引入宠物突触成像 示踪剂11C-UCB-J。在MRI中，耶鲁MRRC产生了许多新颖的方法来表征 个人的功能连接组并将功能组织与行为和临床变量联系起来 总体而言，这两个中心开发了尖端成像技术，并应用这些技术来回答 重要的临床问题。通过创建耶鲁ADRC成像核心（YAIC），我们利用疫苗 耶鲁大学成像优势的经验，可以提供最新的获取和成像数据的分析和分析 专注于发展AD方法的发展。 YAIC将为 获得多模式成像数据的获取，处理和分析，以支持和培训广告调查人员以及 开发下一代成像工具。当前和将来的方法将应用于正在进行的 成像研究以获取人类受试者中丰富，多方面和多模式数据集。另外， 该程序的翻译组成部分考试非人类灵长类动物（NHP）的实用性作为模型 人类广告。成像核心将执行以下特定目的：目标1：开发和优化宠物 图像和数据分析策略，以促进受试者内部和受试者之间的比较。多跟踪器 受试者相关性很重要，涉及淀粉样蛋白，TAU，突触密度和葡萄糖代谢。目标2：到 增强我们基于MR的功能连接组建模，以更好地从功能表型患者进行链接 大脑到行为。这种方法在本地网络时为每个人提供功能概况 并揭示网络组织原则支持这些功能。目标3：开发和丰富多种多样 PET和FMRI之间的模态分析，用于研究内部和受试者之间的研究。 fmri-的组合 与PET可测量的神经变性区域模式的基于基于的连通性可提供理想 理解疾病进展途径的机会。目标4：扩展方法 开发用于人类分析到NHP数据。正在进行的NHP的研究正在进行，提供 将体内宠物和MR成像与验尸测量结果进行比较的机会 神经病理学核心。